This project has been flagged by a community member as inappropriate due to reason below.*
Expert Interview
Slingshot members are talking to an expert! The topic is:
A Second Opinion: Examining Incyte's Phase 3 TRuE-V data for Ruxolitinib Cream (Opzelura) in treating non-segmental vitiligo
Ticker(s): INCYWho's the expert?
Institution: Conway Medical
- Manages about 15 to 20 patients with Prurigo Nodularis and 45 patients with non-segmental vitiligo
- familiar with Haduvio and it's Phase 2b/3 PRISM trial
- Published multiple papers in dermatology
Interview GoalThe goal of this interview is to look into the Phase 3 TRuE-V data for ruxolitinib cream (Opzelura) in treating non-segmental vitiligo
Do you want answers to these questions?
Slingshot Insights Explained
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
